ArticleJournal of ovarian research2009
Mucins in ovarian cancer diagnosis and therapy.
Article in Journal of ovarian research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Mucin-Targeted Antibodies for Ovarian Cancer.Seminars in nuclear medicine · 2025Review
- Investigation of the effect of thymoquinone and doxorubicin on the EGFR/FOXP3 signaling pathway in OVCAR3 human ovarian adenocarcinoma cells.Acta cirurgica brasileira · 2025Article
- Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction.Biomedicines · 2024Review
- Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance.Cancer metastasis reviews · 2024Review
- Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.Journal of ovarian research · 2024Review
- Measuring the multifaceted roles of mucin-domain glycoproteins in cancer.Advances in cancer research · 2023Review
- Cancer immune exclusion: breaking the barricade for a successful immunotherapy.Frontiers in oncology · 2023Review
- Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.International journal of cancer · 2022Article
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- Whole-exome sequencing reveals rare genetic variations in ovarian granulosa cell tumor.Bosnian journal of basic medical sciences · 2022Article
- Article
- Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.Frontiers in oncology · 2022Article
- An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry.ACS nano · 2020Article
- Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function.Frontiers in immunology · 2020Review
- MUC1 gene silencing inhibits proliferation, invasion, and migration while promoting apoptosis of oral squamous cell carcinoma cells.Bioscience reports · 2019Article
- Cancer-associated mucins: role in immune modulation and metastasis.Cancer metastasis reviews · 2019Review
- High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.Oncotarget · 2017Article
- Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.Glycoconjugate journal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most lethal gynecologic malignancy and the five-year survival rate is only 35% after diagnosis. Epithelial ovarian cancer is a highly metastatic disease characterized by widespread peritoneal dissemination and ascites. The death incidences from ovarian cancer could be significantly lowered by developing new methods for the early diagnosis and treatment of this fatal disease. Several potential markers have been identified recently. However, mucins are the most promising markers for ovarian cancer diagnosis. Mucins are large extracellular, heavily glycosylated proteins and their aberrant expression has been implicated in the pathogenesis of a variety of cancers, including ovarian cancer. This review will summarize known facts about the pathological and molecular characteristics of ovarian cancer, the current status of ovarian cancer markers, as well as general information about mucins, the putative role of mucins in the progression of ovarian cancer and their potential use for the early diagnosis and treatment of this disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.